(ITACE) IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ANTI-EGFR MAB NIMOTUZUMAB PLUS ADRIAMYCIN. PHASE I CLINICALTRIAL, FINAL RESULTS

(24%), and surgery only (10.5%). The 5-year overall survival (OS) was 60.5% and 10-year survival rate was 56%. The 5-year relapse free survival was 57.3%. Ten-year OS was indistinguishable between the group that was treated with the combination of surgery/CT and the group that had received CT only (60% versus 61.5%, respectively). In multivariate analysis, high grade lymphoma and complete response were the only significant prognostic factors for OS. Conclusion: The clinical presentation of small intestinal lymphoma is non specific. The prognosis is good. With advancement in endoscopy and interventional radiology, surgery has a limited role in diagnosis. It seems that there is no benefit in terms of overall survival to operating on patients with PSIL.